SCHEMBL19196801

SCHEMBL19196801

CCCc1cc(C(C)(C)C)ccc1NN

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
MAPK1 P28482 2/20 0.43
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HTR1D P28221 5/20 0.38
CYP2D6 P10635 2/20 0.37
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35
MAPT P10636 3/20 0.34
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
PKM P14618 1/20 0.34
RECQL P46063 1/20 0.34
KMT2A Q03164 1/20 0.34
HTR1A P08908 1/20 0.34
HTR1B P28222 1/20 0.34
NR1H4 Q96RI1 1/20 0.33
ATM Q13315 1/20 0.33
HPGD P15428 1/20 0.33
ALOX15 P16050 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20000789 0.86 ALDH1A1 (0.40) ALDH1A1MAPK1LMNASMN1; SMN2HTR1D
SCHEMBL19204117 0.84 ALDH1A1 (0.44) ALDH1A1MAPK1LMNASMN1; SMN2HTR1D
SCHEMBL24627773 0.81 HTR1D (0.43) ALDH1A1MAPK1LMNASMN1; SMN2HTR1D
SCHEMBL21523926 0.76 ATM (0.42) ALDH1A1MAPK1LMNASMN1; SMN2HTR1D
SCHEMBL21449928 0.74 CYP2D6 (0.41) ALDH1A1MAPK1LMNASMN1; SMN2HTR1D
SCHEMBL20207510 0.73 CYP2D6 (0.40) ALDH1A1MAPK1LMNASMN1; SMN2HTR1D
SCHEMBL5165521 0.73 CYP2D6 (0.61) ALDH1A1SMN1; SMN2CYP2D6CYP1A2CYP2C19
SCHEMBL27012358 0.73 CYP2D6 (0.40) ALDH1A1MAPK1LMNASMN1; SMN2HTR1D
SCHEMBL21849299 0.72 HTR1D (0.42) ALDH1A1MAPK1LMNASMN1; SMN2HTR1D
SCHEMBL19779066 0.72 HTR1D (0.36) ALDH1A1LMNAHTR1DMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230038823-A1 CAPSID INHIBITORS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. (US) 2023-02-09 US disclosed
US-11541046-B2 Spirolactone compounds QUIXGEN, INC. (US) 2023-01-03 US disclosed
US-20210145822-A1 Novel Spirolactone Compounds QUIXGEN, INC. (US) 2021-05-20 US disclosed
US-9969689-B2 Aryl ethers and uses thereof PELOTON THERAPEUTICS, INC. (US) 2018-05-15 US disclosed
US-20170217891-A1 ARYL ETHERS AND USES THEREOF PELOTON THERAPEUTICS, INC. 2017-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11541046-B2 Spirolactone compounds ACACA, AKR1C2, AKR1A1 ALDH1A1 40/4885MAPK1 141/4885LMNA 3974/4885
US-20230038823-A1 CAPSID INHIBITORS FOR THE TREATMENT OF HIV HAVCR2, MAVS, CD4 ALDH1A1 3650/4885MAPK1 4065/4885LMNA 2645/4885
US-20210145822-A1 Novel Spirolactone Compounds ACACA, HSD17B10, AKR1C2 ALDH1A1 43/4885MAPK1 163/4885LMNA 4170/4885
US-20170217891-A1 ARYL ETHERS AND USES THEREOF HIF1AN, EGLN2, VHL ALDH1A1 497/4885MAPK1 3395/4885LMNA 4171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.